Down Syndrome
Also known as: Trisomy 21
Methodology & AI Transparency ⓘ
Down Syndrome Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is Down syndrome? Down syndrome is a condition in which a person has an extra chromosome or an extra piece of a chromosome.
- 2 Real-world patient consensus: Diagnostic registry G47.2: Down Syndrome is managed within Sleep Disorders (aka Trisomy 21).
- 3 Typical cash cost range: Workup highlights for Down Syndrome (G47.2): CBT-I behavioral sleep in Down Syndrome (G47.2: efficiency tracking).
- 4 Top reported side effects / signs: Longitudinal Down Syndrome monitoring tracks Insomnia Severity Index in Down Syndrome (G47.2: (ISI)) toward < 7 (G47.2).
Ask our AI Specialists anything about Down Syndrome
What Is Down Syndrome?
What is Down syndrome? Down syndrome is a condition in which a person has an extra chromosome or an extra piece of a chromosome. This extra copy changes how a baby's body and brain develop. It can cause both mental and physical challenges during their lifetime. Even though people with Down syndrome might act and look similar, each person has different abilities. What causes Down syndrome? Chromosomes are tiny "packages" in your cells that contain your genes. Genes carry information, called DNA, that controls what you look like and how your body works. People with Down syndrome have an extra copy of chromosome 21.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Down Syndrome (G47.2) center on fragmented slow-wave/REM sleep in Down Syndrome (G47.2: architecture). Cross-referenced with NIH MeSH (Down Syndrome), targeted sleep disorders interventions aim to normalize Insomnia Severity Index in Down Syndrome (G47.2: (ISI)).
Common Symptoms & Clinical Signs
- • Eyes that slant up
- • Small hands and feet
- • Presentation of Down Syndrome (G47.2): unrefreshing morning waking in Down Syndrome (G47.2: despite adequate hours)
- • Secondary Down Syndrome clinical sign: loud habitual snoring, in Down Syndrome (G47.2: witnessed breathing pauses,)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Down Syndrome Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G47.2 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Insomnia, Sleep Apnea & Sleep Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Insomnia Severity Index in Down Syndrome (G47.2: (ISI)) | < 7 (G47.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Nocturnal Oxygen Saturation in Down Syndrome (G47.2: (SpO2)) | >= 94% nadir > 90% (G47.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Ferritin (Restless in Down Syndrome (G47.2: Legs)) | > 75 ng/mL (G47.2) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Down Syndrome
Treatment selection for Down Syndrome depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Down Syndrome)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Cognitive Effects of Treating Obstructive Sleep: What a 1,926-Participant Study Found Our meta-analysis indicates that CPAP treatment can partially improve cognitive impairment in the population of severe OSA. Journal of Alzheimer's disease : JAD • 2020-01-15 • Meta-Analysis | N = 1,926 | 94/100 | PMID 32310179 ↗ |
| New Insights on Efficacy of downtitration or treatment withdrawal compared with continuous dosing: What a 526-Participant Study Found Baricitinib allows flexibility for patients to downtitrate or stop treatment. The British journal of dermatology • 2023-02-10 • Phase III Randomized Trial | N = 526 | 93/100 | PMID 36763879 ↗ |
| Can This Approach Help? Inside the Latest Research on Heat-Treated Limosilactobacillus fermentum PS150 Improves Sleep Quality with Conclusions : Although group mean scores on sleep symptom scales did not differ significantly in the full cohort, HT-PS150 appeared to modulate sleep-wake regulation by enhancing nocturnal melatonin secretion, attenuating... Nutrients • 2025-12-19 • Randomized Controlled Trial | N = 84 | 88/100 | PMID 41515133 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention In the test of divided attention, patients had fewer false reactions after orexin-A administration. Behavioural brain research • 2014-04-01 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 24406723 ↗ |
| Can This Approach Help? Inside the Latest Research on Ceramides and phospholipids are downregulated with liraglutide treatment: results Compared with placebo, liraglutide treatment led to a significant downregulation in ceramides, phospholipids and triglycerides, which all are linked to higher risk of CVD. BMJ open diabetes research & care • 2021-09-15 • Randomized Controlled Trial | N = 102 | 88/100 | PMID 34518158 ↗ |
Down Syndrome Patient Community & “People Like Me” Threads
Filter Down Syndrome community threads and patient logs by age, biological sex, dosage, and treatment duration.